Update on Bankruptcy Proceedings

On January 13, 2026 the Lund District Court accepted Phase Holographic Imaging PHI AB’s bankruptcy filing and appointed Niklas Ernulf as bankruptcy trustee to manage the company’s assets and liabilities and supervise an orderly liquidation. PHI said it will cooperate with the trustee and disclose material developments under the EU Market Abuse Regulation; no operating metrics or creditor recovery estimates were provided, implying significant downside for equity holders and resolution through insolvency proceedings for creditors.

Analysis

Market structure: PHI’s bankruptcy primarily transfers value to well-capitalized life‑science suppliers and acquirers — winners include large diversified instrument vendors (Danaher DHR, Thermo Fisher TMO, PerkinElmer PKI, Agilent A) who can pick up customers or IP; losers are PHI equity, unsecured creditors, and niche service vendors reliant on PHI revenue. Short‑term pricing power shifts toward incumbents for service/support in Sweden/EMEA over 3–12 months as replacement contracts are signed; net market demand for live‑cell imaging hardware remains steady, so disruption is supply‑side and localized.

Risk assessment: Immediate risk (days) is equity wipeout and legal/claims uncertainty; short term (weeks–months) risk centers on fire‑sale of assets and IP litigation that could depress recovery by 30–70% vs. fair value; long term (3–18 months) tail scenarios include strategic buyouts that revalue assets or contagion causing wider funding stress for European micro‑cap medtechs. Hidden dependencies: transferred OEM/service contracts and research collaborations may create counterparty credit exposures for larger customers; catalysts to monitor are trustee asset sale notices (30–90 days) and any hostile creditor litigation.

Trade implications: Tactical allocation should favor large-cap lab suppliers and underweight/hedge small‑cap biotech/medtech. Implementable trades: take selective long positions in DHR/TMO (1–2% portfolio weights) and hedge via a short small‑cap biotech ETF (XBI) to capture relative outperformance over 3–9 months; buy limited‑risk puts on small‑cap biotech indices for 1–3 month protection. Timing: act within 1–14 days to capture reallocation flows, reassess after trustee’s 60–120 day auction timeline.

Contrarian angles: Consensus treats PHI assets as zero; that may be overdone — strategic acquirers historically pay 20–50% above liquidation value for platform IP and customer lists, creating asymmetric upside for buyers able to bid in 60–180 day auctions. Risk: bidding can ignite competition driving prices up or trigger regulatory/antitrust review if sold to large incumbents; monitor trustee filings and patent assignment records (EU patent register) for trade triggers.

Key Decisions for Investors

• Establish a 1.5% portfolio long in Danaher (DHR) within 10 business days, target +12% absolute return over 3–9 months, set a hard stop-loss at -8% to limit downside if small‑cap contagion widens.
• Initiate a dollar‑neutral pair: long DHR (1.0%) / short XBI (1.0%) to capture expected 200–500bps relative outperformance over 1–3 quarters; unwind on a 15% move in either leg or after trustee announces asset sale (monitor 60–120 day window).
• Buy protective downside: purchase 1–3 month put spread on XBI with strikes ~10%/5% OTM sized to cost no more than 0.5% portfolio risk to hedge small‑cap biotech exposure while keeping upside optionality.
• Allocate up to 0.5% dry‑powder to participate in PHI asset/IP auctions if trustee announces sale (likely 60–180 days); target acquisitions where IP/customer contracts can be integrated with incremental revenue >€2–5m and implied purchase price <3x forecasted year‑one revenue.